Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

oleh: Joyce V. Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila, Pauliina M. Munne, Mariel Savelius, Kathleen E. Houlahan, Daniel Van de Mark, Golzar Hemmati, Grace A. Hernandez, Yibing Zhang, Susan Samson, Carole Baas, Laura J. Esserman, Laura J. van ‘t Veer, Hope S. Rugo, Christina Curtis, Juha Klefström, Mehrdad Matloubian, Andrei Goga

Format: Article
Diterbitkan: Nature Portfolio 2022-06-01

Deskripsi

The oncoprotein c-Myc is often overexpressed in triple negative breast cancer and has a role in tumor progression and resistance to therapy. Here the authors show that elevated MYC expression is correlated with low immune infiltration, diminished MHC-I pathway expression and that CpG/aOX40 treatment could overcome resistance to PD-L1 blockade in MYC-high breast tumors.